Berberine, a candidate drug to control the development of Alzheimer's disease
| Project/Area Number |
20590260
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
General pharmacology
|
|---|
| Research Institution | Saitama Medical University |
|---|
Principal Investigator |
MARUYAMA Kei Saitama Medical University, 医学部, 教授 (30211577)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2010: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2009: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2008: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | アルツハイマー病 / アミロイド / 認可薬剤 / ベルベリン / 併用療法 / セクレターゼ / ネプリライシン / 神経防護 / βアミロイド / 神経防護作用 / 認可薬物 / 多剤併用療法 / 臨床使用 / 安全性 |
|---|
| Research Abstract |
The substances for the treatment of Alzheimer's disease, which decreased Aβ levels, were screened from clinically approved drugs. We identified KM2309 (code name, because of patent application). It inhibited γ-secretase and up-regulated a major Aβ-degrading enzyme neprilysin. Since it has been reported that KM2309 crosses the BBB and it has neuronal protective effect, KM2309 would be a novel drug candidate with safety for Alzheimer's disease.
|
Report
(4 results)
Research Products
(29 results)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Book] MR 薬理学2010
Author(s)
遠藤實(監修), 丸山敬, 淡路健雄(編集)
Total Pages
286
Publisher
恒心社出版
Related Report
-
-
-
-
-
-
-
